Also known as: GRF 1-29, Geref
The first 29 amino acids of natural GHRH. Once approved for children with GH deficiency.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Stimulates the pituitary's own GH release while keeping normal feedback control.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Muscle & growth hormone | B | Human trials (smaller, mixed, or approved outside the US) |
| Sleep | C | Limited human data, case series or practitioner reports |
| Fat loss & weight | C | Limited human data, case series or practitioner reports |
| Longevity & energy | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Subcutaneous
- Half-life
- About 10 to 20 minutes
Reported dosing
200 to 500 mcg (0.2 to 0.5 mg) nightly.
Timing: Bedtime, on an empty stomach.
Cycle: Often 5 nights on, 2 off, for 3 to 6 months.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Injection-site redness
- Flushing, headache
- Dizziness
Who should avoid it
- Active cancer
- Pregnancy
- Hypothyroidism should be treated first
Often combined with
Often combined with ipamorelin or GHRP-2.
Key findings
The brand (Geref) was withdrawn in 2008 for manufacturing reasons, not safety. Small trials in older adults showed higher IGF-1 and some lean-mass gains.
Where it is legal (Oct 2026)
| US | Compounded prescription |
|---|---|
| Canada | Not approved |
| Mexico | Verify locally |
| EU | Not approved |
US: compounded prescription; the brand was withdrawn in 2008 for commercial reasons.
Sources
Open Sermorelin in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.